TP53 and neoplasm: This conclusion is consistent with the TCGA database showing that the receptor tyrosine kinase (RTK)/RAS pathway, involved in cell cycle signaling, was altered in 44% of miBCa patients and that the TP53 tumor suppressor was functionally inactive in 76% of miBCa patients [8], suggesting that targeting cell growth with increasing cell apoptosis can better suppress the BCa progression.